Phase 2 antibody cuts inflammation markers for six months

In a hot-line session in Munich on Aug. 29, Deepak L. Bhatt of Mount Sinai Fuster Heart Hospital presented six-month results for pacibekitug, an investigational antibody from Novartis. In the Phase 2 TRANQUILITY trial, the drug kept inflammation markers down through day 180 in adults with chronic kidney disease and elevated inflammatory risk associated with heart disease.

The study enrolled 143 adults in a randomized, double-blind, placebo-controlled trial. Participants received a placebo or one of three pacibekitug dosing regimens. The antibody targets IL-6, or interleukin-6, a protein involved in immune responses and inflammatory pathways associated with cardiovascular risk. Earlier analyses had shown reductions through 90 days; the new analysis tested whether those effects lasted to 180 days.

They did. Time-averaged reductions in hsCRP — high-sensitivity C-reactive protein, a blood marker of inflammation — ranged from 76% to 89% across the pacibekitug groups on day 180. The placebo group recorded a 7% increase. Other biomarkers linked to IL-6 activity and cardiovascular risk also moved favorably, and the treatment was generally well tolerated, with no new safety signals identified.

The result matters because it shows that a long-acting antibody can sustain suppression of the IL-6 pathway with infrequent dosing, according to Bhatt. Higher doses also produced greater reductions on certain measures, a dose-dependent pattern that supports the drug having a biological effect. But biomarkers are still a step removed from patient outcomes: TRANQUILITY did not establish whether pacibekitug improves cardiovascular outcomes.

So what changes concretely? For patients with chronic kidney disease and elevated inflammatory risk, pacibekitug now has Phase 2 evidence that its intended pathway can be suppressed for six months. For doctors and researchers, the next test is larger cardiovascular-outcome studies to determine whether the biomarker effects translate into improved cardiovascular outcomes.